The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Thursday, August 13, 2026

Subject of the day

PFE

Concerning the House

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

United States · www.pfizer.com

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$62.58B+1.6%
Net income$2.12B-8.1%
Cash from ops$11.70B-2.2%
Quotation

$26.31

-0.31 (-1.2%)

52w hi$27.60
52w lo$22.05
Vol27.52M
As ofAug 12
The Verdict

Hold

Our score +0.15

Short-0.03
Medium+0.28
Long+0.24

computed 2026-08-12

By the Numbers

Pfizer Inc.

Healthcare · Drug Manufacturers - General

Market cap$149.96B
Enterprise value$203.80B
Trailing P/E34.62x
Forward P/E9.10x
EV / EBITDA8.03x
P / S (ttm)2.35x
Profit margin6.8%
Return on equity5.0%
Revenue growth+2.6%
Earnings growth
Debt / equity74.25
Risk Metrics
Beta vs SPX0.40
Corr SPX0.27
Annual vol24.2%
Annual ret-1.7%
Sharpe-0.07
Max DD-28.5%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.19
Sector+0.12
Technical+0.03
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-12

Recent Sessions
DateOpenHighLowCloseVol
Aug 12$26.39$26.43$26.18$26.3127.52M
Aug 11$26.94$27.20$26.47$26.6237.94M
Aug 10$26.59$27.19$26.52$27.0549.79M
Aug 7$26.22$26.76$26.05$26.7642.74M
Aug 6$26.01$26.20$25.81$26.2051.07M